{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T08:30:11Z","timestamp":1785573011141,"version":"3.56.0"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005927","name":"American Society of Colon and Rectal Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005930","name":"ASCRS Research Foundation","doi-asserted-by":"publisher","award":["GR027432"],"award-info":[{"award-number":["GR027432"]}],"id":[{"id":"10.13039\/100005930","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.neo.2026.101309","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:57:49Z","timestamp":1776891469000},"page":"101309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: implications for a precision treatment approach"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4413-3211","authenticated-orcid":false,"given":"Ann T.","family":"Pham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagaraj S.","family":"Nagathihalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9071-1591","authenticated-orcid":false,"given":"Austin R.","family":"Dosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.neo.2026.101309_bib0001","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1038\/bcj.2016.69","article-title":"ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2)","volume":"6","author":"Jiang","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.neo.2026.101309_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102268","article-title":"ATM in immunobiology: From lymphocyte development to cancer immunotherapy","volume":"52","author":"Lee","year":"2025","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-39525-3","article-title":"Prognostic impact of ATM mutations in patients with metastatic colorectal cancer","volume":"9","author":"Randon","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11661-8","article-title":"ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer","volume":"7","author":"Drosos","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0005","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-07749-6","article-title":"The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis","volume":"21","author":"Moslemi","year":"2021","journal-title":"BMC. Cancer"},{"issue":"9","key":"10.1016\/j.neo.2026.101309_bib0006","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.dnarep.2009.04.006","article-title":"Common mechanisms of PIKK regulation","volume":"8","author":"Lovejoy","year":"2009","journal-title":"DNa Repair."},{"issue":"7322","key":"10.1016\/j.neo.2026.101309_bib0007","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature09428","article-title":"An unprecedented nucleic acid capture mechanism for excision of DNA damage","volume":"468","author":"Rubinson","year":"2010","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0008","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nsmb.2831","article-title":"Association of condensin with chromosomes depends on DNA binding by its HEAT-repeat subunits","volume":"21","author":"Piazza","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/jmbi.2001.4624","article-title":"Comparison of ARM and HEAT protein repeats","volume":"309","author":"Andrade","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"15","key":"10.1016\/j.neo.2026.101309_bib0010","doi-asserted-by":"crossref","first-page":"15158","DOI":"10.1074\/jbc.M412065200","article-title":"DNA damage-induced association of ATM with its target proteins requires a protein interaction domain in the N terminus of ATM","volume":"280","author":"Fernandes","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"37","key":"10.1016\/j.neo.2026.101309_bib0011","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1038\/sj.onc.1204665","article-title":"Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53","volume":"20","author":"Turenne","year":"2001","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0012","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.dnarep.2006.01.012","article-title":"gammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes","volume":"5","author":"Stucki","year":"2006","journal-title":"DNa Repair"},{"issue":"12","key":"10.1016\/j.neo.2026.101309_bib0013","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1038\/sj.emboj.7601733","article-title":"ATMIN defines an NBS1-independent pathway of ATM signalling","volume":"26","author":"Kanu","year":"2007","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0014","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nsmb1090","article-title":"Two-step activation of ATM by DNA and the Mre11-Rad50-Nbs1 complex","volume":"13","author":"Dupr\u00e9","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0015","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.celrep.2013.06.039","article-title":"Functional activation of ATM by the prostate cancer suppressor NKX3.1","volume":"4","author":"Bowen","year":"2013","journal-title":"Cell Rep."},{"issue":"41","key":"10.1016\/j.neo.2026.101309_bib0016","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1038\/sj.onc.1206760","article-title":"ATM's leucine-rich domain and adjacent sequences are essential for ATM to regulate the DNA damage response","volume":"22","author":"Chen","year":"2003","journal-title":"Oncogene"},{"issue":"6632","key":"10.1016\/j.neo.2026.101309_bib0017","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/387520a0","article-title":"Interaction between ATM protein and c-Abl in response to DNA damage","volume":"387","author":"Shafman","year":"1997","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0018","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0968-0004(00)01563-2","article-title":"FAT: a novel domain in PIK-related kinases","volume":"25","author":"Bosotti","year":"2000","journal-title":"Trends. Biochem. Sci."},{"key":"10.1016\/j.neo.2026.101309_bib0019","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1146\/annurev-biochem-060614-034335","article-title":"Mechanisms of ATM Activation","volume":"84","author":"Paull","year":"2015","journal-title":"Annu. Rev. Biochem."},{"issue":"5218","key":"10.1016\/j.neo.2026.101309_bib0020","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1126\/science.7792600","article-title":"A single ataxia telangiectasia gene with a product similar to PI-3 kinase","volume":"268","author":"Savitsky","year":"1995","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.neo.2026.101309_bib0021","doi-asserted-by":"crossref","first-page":"15741","DOI":"10.1074\/jbc.M513172200","article-title":"The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM","volume":"281","author":"Jiang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"26","key":"10.1016\/j.neo.2026.101309_bib0022","doi-asserted-by":"crossref","first-page":"13436","DOI":"10.1074\/jbc.M115.708263","article-title":"The dimeric architecture of checkpoint kinases Mec1ATR and Tel1ATM reveal a common structural organization","volume":"291","author":"Sawicka","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"48","key":"10.1016\/j.neo.2026.101309_bib0023","doi-asserted-by":"crossref","first-page":"34277","DOI":"10.1074\/jbc.274.48.34277","article-title":"Localization of a portion of extranuclear ATM to peroxisomes","volume":"274","author":"Watters","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.neo.2026.101309_bib0024","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/ncb3230","article-title":"ATM functions at the peroxisome to induce pexophagy in response to ROS","volume":"17","author":"Zhang","year":"2015","journal-title":"Nat. Cell Biol."},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0025","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2011-08-373639","article-title":"Mitochondrial dysfunction in ataxia-telangiectasia","volume":"119","author":"Valentin-Vega","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.neo.2026.101309_bib0026","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1093\/emboj\/cdg541","article-title":"Requirement of the MRN complex for ATM activation by DNA damage","volume":"22","author":"Uziel","year":"2003","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.neo.2026.101309_bib0027","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1083\/jcb.200906064","article-title":"Autophosphorylation at serine 1981 stabilizes ATM at DNA damage sites","volume":"187","author":"So","year":"2009","journal-title":"J. Cell Biol."},{"issue":"5383","key":"10.1016\/j.neo.2026.101309_bib0028","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1126\/science.281.5383.1674","article-title":"Enhanced phosphorylation of p53 by ATM in response to DNA damage","volume":"281","author":"Banin","year":"1998","journal-title":"Science"},{"issue":"5383","key":"10.1016\/j.neo.2026.101309_bib0029","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1126\/science.281.5383.1677","article-title":"Activation of the ATM kinase by ionizing radiation and phosphorylation of p53","volume":"281","author":"Canman","year":"1998","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1101\/gad.13.2.152","article-title":"A role for ATR in the DNA damage-induced phosphorylation of p53","volume":"13","author":"Tibbetts","year":"1999","journal-title":"Genes Dev."},{"issue":"45","key":"10.1016\/j.neo.2026.101309_bib0031","doi-asserted-by":"crossref","first-page":"42462","DOI":"10.1074\/jbc.C100466200","article-title":"ATM phosphorylates histone H2AX in response to DNA double-strand breaks","volume":"276","author":"Burma","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"51","key":"10.1016\/j.neo.2026.101309_bib0032","doi-asserted-by":"crossref","first-page":"47759","DOI":"10.1074\/jbc.C100569200","article-title":"Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress","volume":"276","author":"Ward","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0033","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1091\/mbc.e04-10-0890","article-title":"Ionizing radiation\u2013dependent \u03b3-H2AX focus formation requires ataxia telangiectasia mutated and ataxia telangiectasia mutated and Rad3-related","volume":"16","author":"Friesner","year":"2005","journal-title":"Mol. Biol. Cell"},{"issue":"17","key":"10.1016\/j.neo.2026.101309_bib0034","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1101\/gad.914401","article-title":"Cell cycle checkpoint signaling through the ATM and ATR kinases","volume":"15","author":"Abraham","year":"2001","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrc1011","article-title":"ATM and related protein kinases: safeguarding genome integrity","volume":"3","author":"Shiloh","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"6830","key":"10.1016\/j.neo.2026.101309_bib0036","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/35071124","article-title":"The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis","volume":"410","author":"Falck","year":"2001","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.neo.2026.101309_bib0037","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M300229200","article-title":"Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents","volume":"278","author":"Xiao","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.neo.2026.101309_bib0038","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nrm1493","article-title":"Checking on DNA damage in S phase","volume":"5","author":"Bartek","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5625","key":"10.1016\/j.neo.2026.101309_bib0039","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0040","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1101\/gad.1067403","article-title":"Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance","volume":"17","author":"Brown","year":"2003","journal-title":"Genes Dev."},{"issue":"5547","key":"10.1016\/j.neo.2026.101309_bib0041","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1065521","article-title":"ATR and ATRIP: partners in checkpoint signaling","volume":"294","author":"Cortez","year":"2001","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0042","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2009.01.024","article-title":"Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks","volume":"33","author":"Shiotani","year":"2009","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.neo.2026.101309_bib0043","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ncb1446","article-title":"Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway","volume":"8","author":"Ziv","year":"2006","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0044","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/1541-7786.MCR-11-0134","article-title":"The ATM Substrate KAP1 controls DNA repair in heterochromatin: regulation by HP1 proteins and serine 473\/824 phosphorylation","volume":"10","author":"White","year":"2012","journal-title":"Mol. Cancer Res."},{"issue":"10","key":"10.1016\/j.neo.2026.101309_bib0045","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.neo.2026.101309_bib0046","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.molcel.2022.05.004","article-title":"Hallmarks of DNA replication stress","volume":"82","author":"Saxena","year":"2022","journal-title":"Mol. Cell"},{"issue":"14","key":"10.1016\/j.neo.2026.101309_bib0047","first-page":"1001","article-title":"The MDM2-p53 interaction","volume":"1","author":"Moll","year":"2003","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0048","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4161\/cc.9.3.10556","article-title":"Mechanism of p53 stabilization by ATM after DNA damage","volume":"9","author":"Cheng","year":"2010","journal-title":"Cell Cycle"},{"issue":"6810","key":"10.1016\/j.neo.2026.101309_bib0049","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0050","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026104","article-title":"The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression","volume":"6","author":"Chen","year":"2016","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0051","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","article-title":"p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage","volume":"11","author":"Reinhardt","year":"2007","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.neo.2026.101309_bib0052","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1101\/gad.1815309","article-title":"The combined status of ATM and p53 link tumor development with therapeutic response","volume":"23","author":"Jiang","year":"2009","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0053","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/15384101.2017.1412147","article-title":"DNA-PK, ATM, and ATR: PIKKing on p53","volume":"17","author":"Ashley","year":"2018","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0054","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1080\/10428194.2018.1542144","article-title":"ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients","volume":"60","author":"Mareckova","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"14","key":"10.1016\/j.neo.2026.101309_bib0055","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1158\/1078-0432.CCR-24-3168","article-title":"Clinicopathologic features, molecular landscape, and prognostic implications of ovarian low-grade serous tumors with histologic transformation","volume":"31","author":"Chui","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.neo.2026.101309_bib0056","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1158\/1078-0432.CCR-23-1122","article-title":"ATMMutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC","volume":"29","author":"Vokes","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.neo.2026.101309_bib0057","doi-asserted-by":"crossref","first-page":"40152","DOI":"10.18632\/oncotarget.10308","article-title":"Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines","volume":"8","author":"Fleury","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.neo.2026.101309_bib0058","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2026.101309_bib0059","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2022.01.037","article-title":"Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors","volume":"166","author":"Paulet","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.neo.2026.101309_bib0060","first-page":"8","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0061","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0062","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1093\/nar\/gkv160","article-title":"Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation","volume":"43","author":"Bakr","year":"2015","journal-title":"Nucleic. Acids. Res."},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003277","article-title":"The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR\u2013mediated double-strand break repair","volume":"9","author":"Wang","year":"2013","journal-title":"PLoS. Genet."},{"issue":"17","key":"10.1016\/j.neo.2026.101309_bib0064","doi-asserted-by":"crossref","first-page":"9710","DOI":"10.1093\/nar\/gkaa723","article-title":"ATM antagonizes NHEJ proteins assembly and DNA-ends synapsis at single-ended DNA double strand breaks","volume":"48","author":"Britton","year":"2020","journal-title":"Nucleic. Acids. Res."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07729-2","article-title":"ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks","volume":"10","author":"Balmus","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0066","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/emboj\/19.3.463","article-title":"The controlling role of ATM in homologous recombinational repair of DNA damage","volume":"19","author":"Morrison","year":"2000","journal-title":"EMBO J."},{"issue":"21","key":"10.1016\/j.neo.2026.101309_bib0067","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/emboj.2009.276","article-title":"ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2","volume":"28","author":"Beucher","year":"2009","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0068","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The Trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.neo.2026.101309_bib0069","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATMLoss Confers Greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer","volume":"80","author":"Rafiei","year":"2020","journal-title":"Cancer Res."},{"issue":"6003","key":"10.1016\/j.neo.2026.101309_bib0070","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1126\/science.1192912","article-title":"ATM Activation by oxidative stress","volume":"330","author":"Guo","year":"2010","journal-title":"Science"},{"issue":"512","key":"10.1016\/j.neo.2026.101309_bib0071","doi-asserted-by":"crossref","first-page":"eaan5598","DOI":"10.1126\/scisignal.aan5598","article-title":"ATM directs DNA damage responses and proteostasis via genetically separable pathways","volume":"11","author":"Lee","year":"2018","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neo.2026.101309_bib0072","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2015.11.003","article-title":"Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases","volume":"157","author":"Buendia","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neo.2026.101309_bib0073","first-page":"994","article-title":"Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients","volume":"8","author":"Navrkalova","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.neo.2026.101309_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101511","article-title":"Mitochondria at the crossroads of ATM-mediated stress signaling and regulation of reactive oxygen species","volume":"32","author":"Lee","year":"2020","journal-title":"Redox. Biol."},{"key":"10.1016\/j.neo.2026.101309_bib0075","article-title":"Ataxia-telangiectasia mutated is located in cardiac mitochondria and impacts oxidative phosphorylation","volume":"9","author":"Blignaut","year":"2019"},{"key":"10.1016\/j.neo.2026.101309_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2024.103269","article-title":"Oxidative stress and the multifaceted roles of ATM in maintaining cellular redox homeostasis","volume":"75","author":"Lee","year":"2024","journal-title":"Redox. Biol."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0077","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tibs.2011.10.002","article-title":"The ATM protein kinase and cellular redox signaling: beyond the DNA damage response","volume":"37","author":"Ditch","year":"2012","journal-title":"Trends. Biochem. Sci."},{"key":"10.1016\/j.neo.2026.101309_bib0078","first-page":"8","article-title":"ATM Kinase-Dependent Regulation of Autophagy: A Key Player in Senescence?","author":"Stagni","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"17","key":"10.1016\/j.neo.2026.101309_bib0079","doi-asserted-by":"crossref","first-page":"14729","DOI":"10.18632\/oncotarget.4411","article-title":"ATM in senescence","volume":"6","author":"Aird","year":"2015","journal-title":"Oncotarget."},{"issue":"24","key":"10.1016\/j.neo.2026.101309_bib0080","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1016\/j.molcel.2025.11.006","article-title":"Attenuation of ATM signaling by ROS delays replicative senescence at physiological oxygen","volume":"85","author":"Stuart","year":"2025","journal-title":"Mol. Cell"},{"issue":"52","key":"10.1016\/j.neo.2026.101309_bib0081","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2518589122","article-title":"ATM interaction with GRP94 modulates oncogenic receptor expression and signaling and microglial activation","volume":"122","author":"Burrell","year":"2025","journal-title":"Proc. Natl. Acad. Sci. u S. a"},{"issue":"5828","key":"10.1016\/j.neo.2026.101309_bib0082","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Matsuoka","year":"2007","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.neo.2026.101309_bib0083","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.embor.7400210","article-title":"ATM and ataxia telangiectasia","volume":"5","author":"Mckinnon","year":"2004","journal-title":"EMBo Rep."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0084","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/genes10010025","article-title":"Targeting DNA double-strand break repair pathways to improve radiotherapy response","volume":"10","author":"Toulany","year":"2019","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.neo.2026.101309_bib0086","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.4161\/cc.10.7.15231","article-title":"A minimally invasive assay for individual assessment of the ATM\/CHEK2\/p53 pathway activity","volume":"10","author":"Kabacik","year":"2011","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0087","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/djaa095","article-title":"Pathogenic ATMMutations in cancer and a genetic basis for radiotherapeutic efficacy","volume":"113","author":"Pitter","year":"2021","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"278","key":"10.1016\/j.neo.2026.101309_bib0088","doi-asserted-by":"crossref","first-page":"278ra34","DOI":"10.1126\/scitranslmed.aaa4214","article-title":"Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy","volume":"7","author":"Moding","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0089","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142158","article-title":"Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models","volume":"131","author":"Deland","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.23761","article-title":"Chemotherapy induced DNA damage response","volume":"14","author":"Woods","year":"2013","journal-title":"Cancer Biol. Ther."},{"issue":"47","key":"10.1016\/j.neo.2026.101309_bib0091","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg2263","article-title":"ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer","volume":"9","author":"Zhou","year":"2023","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0092","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.neo.2026.101309_bib0093","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0094","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1083\/jcb.201212058","article-title":"Oncogenes induce genotoxic stress by mitotic processing of unusual replication intermediates","volume":"200","author":"Neelsen","year":"2013","journal-title":"J. Cell Biol."},{"issue":"7119","key":"10.1016\/j.neo.2026.101309_bib0095","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nature05268","article-title":"Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints","volume":"444","author":"Bartkova","year":"2006","journal-title":"Nature"},{"issue":"7119","key":"10.1016\/j.neo.2026.101309_bib0096","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nature05327","article-title":"Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication","volume":"444","author":"Di Micco","year":"2006","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.neo.2026.101309_bib0097","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-22-0685","article-title":"Selective Inhibition of ATM-dependent double-strand break repair and checkpoint control synergistically enhances the efficacy of ATR INHIBITORS","volume":"22","author":"Turchick","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0098","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.neo.2026.101309_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2024.150517","article-title":"Simultaneous inhibition of ATM, ATR, and DNA-PK causes synergistic lethality","volume":"738","author":"Kato","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"22","key":"10.1016\/j.neo.2026.101309_bib0100","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/s41388-025-03343-x","article-title":"Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer","volume":"44","author":"Hofstad","year":"2025","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0101","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2026.101309_bib0102","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-24-1500","article-title":"Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects","author":"Yap","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2026.101309_bib0103","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0104","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.neo.2026.101309_bib0105","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1172\/JCI43976","article-title":"Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells","volume":"121","author":"Connell","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0106","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/PL00008656","article-title":"Characterization of a Saccharomyces cerevisiae homologue of Schizosaccharomyces pombe Chk1 involved in DNA-damage-induced M-phase arrest","volume":"262","author":"Liu","year":"2000","journal-title":"Mol. Gen. Genet."},{"issue":"18","key":"10.1016\/j.neo.2026.101309_bib0107","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.1128\/MCB.00562-06","article-title":"Differential roles of ATM- and Chk2-mediated phosphorylations of hdmx in response to DNA damage","volume":"26","author":"Pereg","year":"2006","journal-title":"Mol. Cell Biol."},{"issue":"56","key":"10.1016\/j.neo.2026.101309_bib0108","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.1038\/sj.onc.1210880","article-title":"ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks","volume":"26","author":"Lavin","year":"2007","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.neo.2026.101309_bib0109","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0962-8924(01)02142-0","article-title":"Triggering the all-or-nothing switch into mitosis","volume":"11","author":"O'Farrell","year":"2001","journal-title":"Trends. Cell Biol."},{"issue":"22","key":"10.1016\/j.neo.2026.101309_bib0110","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.4161\/cc.5.22.3463","article-title":"cell cycle synchronization at the G2\/M phase border by reversible inhibition of CDK1","volume":"5","author":"Vassilev","year":"2006","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0111","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1083\/jcb.200702034","article-title":"An essential role for Cdk1 in S phase control is revealed via chemical genetics in vertebrate cells","volume":"178","author":"Hochegger","year":"2007","journal-title":"J. Cell Biol."},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0112","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tcb.2006.04.002","article-title":"Cdc25: mechanisms of checkpoint inhibition and recovery","volume":"16","author":"Karlsson-Rosenthal","year":"2006","journal-title":"Trends. Cell Biol."},{"issue":"11","key":"10.1016\/j.neo.2026.101309_bib0113","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/sj.onc.1207394","article-title":"Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis","volume":"23","author":"Busino","year":"2004","journal-title":"Oncogene"},{"issue":"5331","key":"10.1016\/j.neo.2026.101309_bib0114","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.277.5331.1501","article-title":"Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216","volume":"277","author":"Peng","year":"1997","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(03)00048-5","article-title":"Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A","volume":"3","author":"S\u00f8rensen","year":"2003","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0116","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.28226","article-title":"Roles of Chk1 in cell biology and cancer therapy","volume":"134","author":"Zhang","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0117","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11596-025-00055-x","article-title":"FOXM1 promotes non-small cell lung cancer progression by increasing CHEK1 expression","volume":"45","author":"Lu","year":"2025","journal-title":"Curr. Med. Sci."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0118","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-025-03411-w","article-title":"Co-inhibition of Notch1 and ChK1 triggers genomic instability and melanoma cell death increasing the lifespan of mice bearing melanoma brain metastasis","volume":"44","author":"Thakur","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0119","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-025-07912-6","article-title":"CHK1 inhibition increases the therapeutic response to radiotherapy via antitumor immunity in ARID1A-deficient colorectal cancer","volume":"16","author":"Chen","year":"2025","journal-title":"Cell Death. Dis."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0120","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5455\/medarh.2023.77.8-12","article-title":"The prevalence of CHEK1 and CHEK2 mutations in prostate cancer: a retrospective cohort study","volume":"77","author":"Alorjani","year":"2023","journal-title":"Med. Arch."},{"issue":"10","key":"10.1016\/j.neo.2026.101309_bib0121","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3390\/cells14100748","article-title":"Cancer vulnerabilities through targeting the ATR\/Chk1 and ATM\/Chk2 Axes in the context of DNA damage","volume":"14","author":"Fernandez","year":"2025","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0122","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/cancers15030735","article-title":"The combination of ATM and Chk1 inhibitors induces synthetic lethality in colorectal cancer cells","volume":"15","author":"Tozaki","year":"2023","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.neo.2026.101309_bib0123","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.3390\/ijms20153700","article-title":"Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells","volume":"20","author":"Ando","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0124","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1039\/C6MD00439C","article-title":"ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells","volume":"8","author":"Ronco","year":"2017","journal-title":"Medchemcomm."},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(18)30009-3","article-title":"Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study","volume":"19","author":"Lee","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.neo.2026.101309_bib0126","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1634\/theoncologist.2020-0491","article-title":"A phase ii single arm pilot study of the CHK1 inhibitor prexasertib (LY2606368) in BRCAwild-type, advanced triple-negative breast cancer","volume":"25","author":"Gatti-Mays","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0127","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47215-6","article-title":"The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial","volume":"15","author":"Giudice","year":"2024","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.neo.2026.101309_bib0128","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1158\/1078-0432.CCR-17-3347","article-title":"Evaluation of prexasertib, a checkpoint kinase 1 inhibitor, in a phase ib study of patients with squamous cell carcinoma","volume":"24","author":"Hong","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0129","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/gutjnl-2016-312623","article-title":"CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells","volume":"67","author":"Manic","year":"2018","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41416-023-02279-x","article-title":"A Phase 1\/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer","volume":"129","author":"Kristeleit","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0131","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1158\/1078-0432.CCR-22-2074","article-title":"A Phase I\/II Trial of Oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer","volume":"29","author":"Jones","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.neo.2026.101309_bib0132","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1158\/2159-8290.CD-14-0380","article-title":"Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy","volume":"4","author":"Al-Ahmadie","year":"2014","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.neo.2026.101309_bib0133","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.neo.2026.101309_bib0134","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0076-6879(05)09029-4","article-title":"Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair","volume":"409","author":"Dantzer","year":"2006","journal-title":"Methods Enzym."},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-Ribose) polymerase in tumors fromBRCAmutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.neo.2026.101309_bib0136","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0137","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0138","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tranon.2017.01.007","article-title":"ATM-deficient colorectal cancer cells are sensitive to the PARP inhibitor olaparib","volume":"10","author":"Wang","year":"2017","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.neo.2026.101309_bib0139","series-title":"Frontiers in Oncology","first-page":"14","article-title":"PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1\/2 and RAD51 downregulation","author":"Muvaffak","year":"2024"},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-09-0872","article-title":"ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-Ribose) polymerase-1 inhibitors","volume":"9","author":"Williamson","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0141","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/emmm.201200229","article-title":"Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53","volume":"4","author":"Williamson","year":"2012","journal-title":"EMBo Mol. Med."},{"issue":"13","key":"10.1016\/j.neo.2026.101309_bib0142","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.4161\/cc.29212","article-title":"Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines","volume":"13","author":"Kubota","year":"2014","journal-title":"Cell Cycle"},{"issue":"15","key":"10.1016\/j.neo.2026.101309_bib0143","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.3390\/ijms26157420","article-title":"Assessing determinants of response to PARP inhibition in germline ATM mutant melanoma","volume":"26","author":"Allavena","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0144","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.neo.2026.101309_bib0145","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP Inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0146","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2026.101309_bib0147","article-title":"Phase II Trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway-deficient neoplasms","volume":"8","author":"George","year":"2024","journal-title":"JCo Precis. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0148","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"33","key":"10.1016\/j.neo.2026.101309_bib0149","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.60.0320","article-title":"Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer","volume":"33","author":"Bang","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101309_bib0150","article-title":"Synthetic lethality beyond BRCA: A Phase I study of rucaparib and irinotecan in metastatic solid tumors with homologous recombination-deficiency mutations beyond BRCA1\/2","volume":"8","author":"Tsang","year":"2024","journal-title":"JCo Precis. Oncol."},{"issue":"19","key":"10.1016\/j.neo.2026.101309_bib0151","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic Castration-resistant prostate cancer with DNA repair defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0152","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol. Cancer"},{"issue":"25","key":"10.1016\/j.neo.2026.101309_bib0153","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.neo.2026.101309_bib0154","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41416-019-0565-8","article-title":"Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated\/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells","volume":"121","author":"Jette","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.neo.2026.101309_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115537","article-title":"DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition","volume":"44","author":"Hayes","year":"2025","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.neo.2026.101309_bib0156","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0157","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2022.5218","article-title":"Avelumab Plus talazoparib in patients With BRCA1\/2- or ATM-altered advanced solid tumors","volume":"9","author":"Schram","year":"2023","journal-title":"JAMa Oncol."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0158","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cell.2005.05.029","article-title":"Cdk1-dependent regulation of the mitotic inhibitor wee1","volume":"122","author":"Harvey","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.neo.2026.101309_bib0159","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104710","article-title":"WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials","volume":"211","author":"Thangaretnam","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.neo.2026.101309_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.05.001","article-title":"Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy","volume":"35","author":"Fang","year":"2019","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0161","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4143\/crt.2021.473","article-title":"Inhibition of WEE1 potentiates sensitivity to PARP inhibitor in biliary tract cancer","volume":"54","author":"Seo","year":"2022","journal-title":"Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.neo.2026.101309_bib0162","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.18632\/oncotarget.14089","article-title":"Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading","volume":"8","author":"Hauge","year":"2017","journal-title":"Oncotarget."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0163","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1474-8","article-title":"Combined inhibition of the cell cycle related proteins Wee1 and Chk1\/2 induces synergistic anti-cancer effect in melanoma","volume":"15","author":"Magnussen","year":"2015","journal-title":"BMC. Cancer"},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0164","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1172\/JCI122622","article-title":"Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis","volume":"129","author":"Bukhari","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4143\/crt.2019.183","article-title":"Therapeutic Co-targeting of WEE1 and ATM downregulates PD-L1 expression in pancreatic cancer","volume":"52","author":"Jin","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.neo.2026.101309_bib0166","first-page":"13","article-title":"Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma","author":"Bruyer","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2026.101309_bib0167","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2023.05.063","article-title":"WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study","volume":"174","author":"Embaby","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.neo.2026.101309_bib0168","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","article-title":"A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma","volume":"34","author":"Xing","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.neo.2026.101309_bib0169","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","article-title":"Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","volume":"21","author":"Williams","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0170","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad031","article-title":"DNA mismatch repair in cancer immunotherapy","volume":"5","author":"Guan","year":"2023","journal-title":"NAR. Cancer"},{"issue":"7","key":"10.1016\/j.neo.2026.101309_bib0171","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06911-3","article-title":"ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death. Dis."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0172","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139333","article-title":"ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS\/STING activation","volume":"131","author":"Hu","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neo.2026.101309_bib0173","first-page":"11","article-title":"ATM mutations benefit bladder cancer patients treated with immune checkpoint inhibitors by acting on the tumor immune microenvironment","author":"Yi","year":"2020","journal-title":"Front. Genet."},{"issue":"9","key":"10.1016\/j.neo.2026.101309_bib0174","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/cells12091288","article-title":"ATM inhibition-induced ISG15\/IFI27\/OASL is correlated with immunotherapy response and inflamed immunophenotype","volume":"12","author":"Huang","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.neo.2026.101309_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216642","article-title":"Inhibition of ATM promotes PD-L1 expression by activating JNK\/c-Jun\/TNF-\u03b1 signaling axis in triple-negative breast cancer","volume":"586","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"issue":"15","key":"10.1016\/j.neo.2026.101309_bib0176","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","article-title":"Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy","volume":"79","author":"Zhang","year":"2019","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0177","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010548","article-title":"The cold immunological landscape of ATM-deficient cancers","volume":"13","author":"Sinha","year":"2025","journal-title":"J. ImmunOther Cancer"},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0178","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.03.052","article-title":"Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype","volume":"128","author":"Micol","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0179","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/cge.12453","article-title":"Ataxia telangiectasia: more variation at clinical and cellular levels","volume":"87","author":"Taylor","year":"2015","journal-title":"Clin. Genet."},{"issue":"16","key":"10.1016\/j.neo.2026.101309_bib0180","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/cancers15164195","article-title":"Relevance of ATM status in driving sensitivity to DNA damage response inhibitors in patient-derived xenograft models","volume":"15","author":"Karmokar","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.neo.2026.101309_bib0181","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/bcr2919","article-title":"Rare variants in the ATMgene and risk of breast cancer","volume":"13","author":"Goldgar","year":"2011","journal-title":"Breast. Cancer Res."},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0182","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1086\/301706","article-title":"ATM Mutations and Phenotypes in Ataxia-Telangiectasia Families in the British Isles: Expression of Mutant ATM and the Risk of Leukemia, Lymphoma, and Breast Cancer","volume":"62","author":"Stankovic","year":"1998","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0183","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/carcin\/bgl237","article-title":"Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer","volume":"28","author":"Pylk\u00e4s","year":"2007","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0184","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/1098-1004(200009)16:3<232::AID-HUMU6>3.0.CO;2-L","article-title":"Characterization of ATM mutations in 41 Nordic families with ataxia telangiectasia","volume":"16","author":"Laake","year":"2000","journal-title":"Hum. Mutat."},{"issue":"9","key":"10.1016\/j.neo.2026.101309_bib0185","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1182\/blood-2002-02-0570","article-title":"Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement","volume":"101","author":"Oguchi","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.neo.2026.101309_bib0186","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ajhg.2009.08.018","article-title":"Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer","volume":"85","author":"Tavtigian","year":"2009","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.neo.2026.101309_bib0187","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1940-6207.CAPR-20-0448","article-title":"Germline pathogenic variants in the ataxia telangiectasia mutated (ATM) Gene are associated with high and moderate risks for multiple cancers","volume":"14","author":"Hall","year":"2021","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.neo.2026.101309_bib0188","first-page":"5","article-title":"Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors","author":"Yamamoto","year":"2016","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.neo.2026.101309_bib0189","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1158\/1078-0432.CCR-23-1763","article-title":"Ataxia-telangiectasia mutated loss-of-function displays variant and tissue-specific differences across tumor types","volume":"30","author":"Pili\u00e9","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0190","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1158\/0008-5472.CAN-20-2447","article-title":"The cancer-associated ATM R3008H mutation reveals the link between ATM activation and its exchange","volume":"81","author":"Milanovic","year":"2021","journal-title":"Cancer Res."},{"issue":"7424","key":"10.1016\/j.neo.2026.101309_bib0191","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.neo.2026.101309_bib0192","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2012.081620","article-title":"ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin","volume":"98","author":"Navrkalova","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0193","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.neo.2026.101309_bib0194","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1073\/pnas.0831102100","article-title":"Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma","volume":"100","author":"Fang","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.neo.2026.101309_bib0195","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2002-02-0382","article-title":"ATM mutations are associated with inactivation of theARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma","volume":"100","author":"Gr\u00f8nb\u00e6k","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0196","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1083\/jcb.201204098","article-title":"Kinase-dead ATM protein causes genomic instability and early embryonic lethality in mice","volume":"198","author":"Yamamoto","year":"2012","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0197","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng958","article-title":"Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer","volume":"32","author":"Spring","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2026.101309_bib0198","first-page":"12","article-title":"Case report: olaparib shows satisfactory clinical outcomes against small cell esophageal carcinoma with ATM mutation","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0199","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1073\/pnas.012329699","article-title":"Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer","volume":"99","author":"Scott","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.neo.2026.101309_bib0200","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41422-019-0205-0","article-title":"Structural insights into the activation of ATM kinase","volume":"29","author":"Xiao","year":"2019","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.neo.2026.101309_bib0201","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141906","article-title":"Concurrent mutations in ATM and genes associated with common \u03b3 chain signaling in peripheral T cell lymphoma","volume":"10","author":"Simpson","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.neo.2026.101309_bib0202","first-page":"13","article-title":"Immune checkpoint inhibitors in peripheral T-cell lymphoma","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.neo.2026.101309_bib0203","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-022-04625-3","article-title":"New human ATM variants are able to regain ATM functions in ataxia telangiectasia disease","volume":"79","author":"Ricci","year":"2022","journal-title":"Cell Mol. Life Sci."},{"issue":"11","key":"10.1016\/j.neo.2026.101309_bib0204","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","article-title":"ATM deficiency is associated with sensitivity to PARP1- and ATR inhibitors in lung adenocarcinoma","volume":"77","author":"Schmitt","year":"2017","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0205","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes \u2014 association analysis in more than 113,000 women","volume":"384","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neo.2026.101309_bib0206","first-page":"440","article-title":"A population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021"},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0207","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.neo.2026.101309_bib0208","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1158\/1078-0432.CCR-22-1483","article-title":"Clinico-genomic characterization of ATM and HRD in pancreas cancer: application for practice","volume":"28","author":"Park","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.neo.2026.101309_bib0209","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"22","key":"10.1016\/j.neo.2026.101309_bib0210","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1002\/cam4.4778","article-title":"Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance","volume":"11","author":"Brady","year":"2022","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.neo.2026.101309_bib0211","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jnci\/djz124","article-title":"Germline pathogenic variants in 7636 japanese patients with prostate cancer and 12 366 controls","volume":"112","author":"Momozawa","year":"2020","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.neo.2026.101309_bib0212","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.neo.2026.101309_bib0213","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdz132","article-title":"Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers","volume":"30","author":"Nones","year":"2019","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.neo.2026.101309_bib0214","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/genes12050616","article-title":"Clinicopathologic profile of breast cancer in germline ATM and CHEK2 mutation carriers","volume":"12","author":"Toss","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.neo.2026.101309_bib0215","first-page":"13","article-title":"Atypical ATMs: broadening the phenotypic spectrum of ATM-associated hereditary cancer","author":"Borja","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0216","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0217","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V99.1.300","article-title":"Ataxia telangiectasia mutated\u2013deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage","volume":"99","author":"Stankovic","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.neo.2026.101309_bib0218","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V98.3.814","article-title":"p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative toTP53 mutation","volume":"98","author":"Pettitt","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.neo.2026.101309_bib0219","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11895","article-title":"Association of tumor protein p53 and ataxia-telangiectasia mutated comutation with response to immune checkpoint inhibitors and mortality in patients with non\u2013small cell lung cancer","volume":"2","author":"Chen","year":"2019","journal-title":"JAMa Netw. Open."},{"issue":"13","key":"10.1016\/j.neo.2026.101309_bib0220","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/1078-0432.CCR-22-3413","article-title":"Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer","volume":"29","author":"Ricciuti","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.neo.2026.101309_bib0221","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1038\/s41591-025-03732-5","article-title":"Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer","volume":"31","author":"Skoulidis","year":"2025","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.neo.2026.101309_bib0222","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.neo.2026.101309_bib0223","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-24-0154","article-title":"Genotype-directed synthetic cytotoxicity of ATR inhibition with radiotherapy","volume":"30","author":"Ng","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.neo.2026.101309_bib0224","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"Hirai","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"18","key":"10.1016\/j.neo.2026.101309_bib0225","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3390\/cancers16183136","article-title":"WEE1 inhibitor adavosertib exerts antitumor effects on colorectal cancer, especially in cases with p53 mutations","volume":"16","author":"Ariyoshi","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.neo.2026.101309_bib0226","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-2224-7","article-title":"Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors","volume":"11","author":"Hubackova","year":"2020","journal-title":"Cell Death. Dis."},{"issue":"9","key":"10.1016\/j.neo.2026.101309_bib0227","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/jnci\/djy028","article-title":"The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers","volume":"110","author":"Weigelt","year":"2018","journal-title":"JNCI: J. Natl. Cancer Inst."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:46:23Z","timestamp":1783140383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626000382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":227,"alternative-id":["S1476558626000382"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101309","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: implications for a precision treatment approach","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101309"}}